

#### **Contents**

Hodgkin and Non-Hodgkin Lymphoma Pre-Infusion (F2018 R7).....1

# Hodgkin and Non-Hodgkin Lymphoma Pre-Infusion (F2018 R7)

#### Disease assessment at diagnosis

- Q1 "Specify the lymphoma histology (at diagnosis)"
  - Update: Lymphoma histology classifications were previously updated on the Disease Classification Form (F2402) updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community. We are now updating the disease classifications on the Hodgkin and Non-Hodgkin Lymphoma Pre-Infusion (F2018) to match the disease classifications on F2402.
    - ~See table below for detailed list of changes
  - <u>Rationale</u>: The discrepancy between the lymphoma histology classifications between F2402 and F2018 has caused data quality issues. Updating the histology classifications on F2018 should alleviate these issues.

#### Disease assessment at diagnosis

- Q84 "Specify the lymphoma histology (at transformation)"
  - Update: Lymphoma histology classifications were previously updated on the Disease Classification Form (F2402) updated to reflect changes by the World Health Organization (WHO) (or similar international consensus organizations) and feedback from experts in the transplant community. We are now updating the disease classifications on the Hodgkin and Non-Hodgkin Lymphoma Pre-Infusion (F2018) to match the disease classifications on F2402.
    - ~See table below for detailed list of changes
  - <u>Rationale</u>: The discrepancy between the lymphoma histology classifications between F2402 and F2018 has caused data quality issues. Updating the histology classifications on F2018 should alleviate these issues.

2018 R6	Data Change Description	2018 R7
Hodgkin Lymphoma Codes	Replacement	Hodgkin Lymphoma
Hodgkin lymphoma, not otherwise specified	Replacement	Classic Hodgkin lymphoma
Lymphocyte depleted	No change	Lymphocyte depleted
Lymphocyte-rich	No change	Lymphocyte-rich
Mixed cellularity	No change	Mixed cellularity
Nodular lymphocyte predominant Hodgkin lymphoma	No change	Nodular lymphocyte predominant Hodgkin lymphoma
Nodular sclerosis	No change	Nodular sclerosis

CIBMTR® is a research collaboration between the Medical College of Wisconsin and NMDP. This document is proprietary and confidential. No part of this may be disclosed in any manner without the prior written consent of CIBMTR.



Non-Hodgkin Lymphoma Codes	Removal	
	Addition	Burkitt lymphoma
Burkitt lymphoma	No change	Burkitt lymphoma
B-cell Neoplasms	Removal	, , , , , , , , , , , , , , , , , , ,
	Addition	Large B-cell lymphomas
ALK+ large B-cell lymphoma	Replacement	ALK-positive large B-cell lymphoma
Diffuse, large B-cell lymphoma-	Replacement	Diffuse large B-cell lymphomaActivated
Activated B-cell type (non-GCB)		B-cell subtype
DLBCL associated with chronic	Replacement	Diffuse large B-cell lymphoma associated
inflammation		with chronic inflammation
Diffuse, large B-cell lymphoma-	Replacement	Diffuse large B-cell lymphoma, Germinal
Germinal center B-cell type High-grade B-cell lymphoma, with	Replacement	Center B-cell subtype Diffuse large B-cell lymphoma / high
MYC and BCL2 and/or BCL6	Replacement	grade B-cell lymphoma with MYC and
rearrangements		BCL2 rearrangements
	Addition	Diffuse large B-cell lymphoma / high
		grade B-cell lymphoma with MYC and
	A d d:+: a a	BCL6 rearrangements
	Addition	Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC, BCL2,
		and BCL6 rearrangements
Diffuse large B-cell Lymphoma (cell	Replacement	Diffuse large B-cell lymphoma, NOS
of origin unknown)		
EBV+ DLBCL, NOS	Replacement	EBV-positive diffuse large B-cell lymphoma
	Addition	Fibrin-associated large B-cell lymphoma
	Addition	Fluid overload-associated large B-cell lymphoma
Burkitt-like lymphoma with 11q aberration	Replacement	High-grade B-cell lymphoma with 11q aberrations
Intravascular large B-cell lymphoma	No change	Intravascular large B-cell lymphoma
Large B-cell lymphoma with IRF4 rearrangement	No change	Large B-cell lymphoma with IRF4 rearrangement
Lymphomatoid granulomatosis	No change	Lymphomatoid granulomatosis
B-cell lymphoma, unclassifiable,	Replacement	Mediastinal grey zone lymphoma
with features intermediate between		
DLBCL and classical Hodgkin		
lymphoma Plasmablastic lymphoma	No change	Plasmablastic lymphoma
Primary cutaneous DLBCL, leg type	Replacement	Primary cutaneous diffuse large B-cell
	·	lymphoma, leg type
Primary mediastinal (thymic) large B-cell lymphoma	Replacement	Primary mediastinal large B-cell lymphoma
T-cell / histiocytic rich large B-cell	Replacement	T-cell / histiocyte-rich large B-cell
High-grade B-cell lymphoma, NOS	No change	lymphoma High-grade B-cell lymphoma, NOS
riigii grade b celi lymphoma, NOS	110 change	riigii grade b celi lymphoma, 1105



	Addition	Primary large B-cell lymphoma of immune-privileged sites
Primary diffuse, large B-cell lymphoma of the CNS	Replacement	Primary large B-cell lymphoma of the CNS
	Addition	Primary large B-cell lymphoma of the testis
	Addition	Primary large B-cell lymphoma of the vitreoretina
	Addition	KSHV / HHV8-associated B-cell lymphoid proliferations and lymphomas
HHV8+ DLBCL, NOS	Replacement	KSHV / HHV8-positive diffuse large B-cell lymphoma
Primary effusion lymphoma	No change	Primary effusion lymphoma
	Addition	Lymphoplasmacytic lymphoma
Waldenstrom macroglobulinemia / Lymphoplasmacytic lymphoma	Replacement	Lymphoplasmacytic lymphoma
	Addition	IgM-LPL/Waldenstrom
	۸ ط ط:۴:۵ ۵	macroglobulinemia
	Addition	Non-IgM-LPL/Waldenstrom
,	Addition	macroglobulinemia  Marginal zone lymphoma
Extranodal marginal zone B-cell	Replacement	Extranodal marginal zone lymphoma of
lymphoma of mucosal associated lymphoid tissue type (MALT)	Replacement	mucosa-associated lymphoid tissue
Nodal marginal zone B-cell lymphoma (± monocytoid B-cells)	Replacement	Nodal marginal zone lymphoma
Pediatric nodal marginal zone lymphoma	Replacement	Pediatric marginal zone lymphoma
	Addition	Primary cutaneous marginal zone lymphoma
	Addition	Splenic B-cell lymphomas
Splenic B-cell lymphoma/leukemia, unclassifiable	Replacement	Splenic, B-cell lymphoma/leukemia with prominent nucleoli
Splenic diffuse red pulp small B-cell lymphoma	No change	Splenic diffuse red pulp small B-cell lymphoma
Splenic marginal zone B-cell lymphoma	Replacement	Splenic marginal zone lymphoma
	Addition	Follicular lymphoma
Duodenal-type follicular lymphoma	No change	Duodenal-type follicular lymphoma
Follicular, mixed, small cleaved and large cell (Grade II follicle center lymphoma)	No change	Follicular, mixed, small cleaved and large cell (Grade II follicle center lymphoma)
Follicular, predominantly large cell (Grade IIIA follicle center lymphoma)	No change	Follicular, predominantly large cell (Grade IIIA follicle center lymphoma)



Follicular, predominantly large cell	No change	Follicular, predominantly large cell
(Grade IIIB follicle center		(Grade IIIB follicle center lymphoma)
lymphoma)		
Follicular, predominantly large cell (Grade IIIA vs IIIB not specified)	No change	Follicular, predominantly large cell (Grade IIIA vs IIIB not specified)
Follicular, predominantly small	No change	Follicular, predominantly small cleaved
cleaved cell (Grade I follicle center		cell (Grade I follicle center lymphoma)
lymphoma) Pediatric-type follicular lymphoma	No change	Pediatric-type follicular lymphoma
Follicular (grade unknown)	No change	Follicular (grade unknown)
Tollicular (grade driknown)	Addition	Cutaneous follicle center lymphoma
Primary cutaneous follicle center	No change	Primary cutaneous follicle center
lymphoma	ino change	lymphoma
7,111,0111.01	Addition	Mantle cell lymphoma
Mantle cell lymphoma	No change	Mantle cell lymphoma
	Addition	Leukemic non-nodal mantle cell
		lymphoma
	Addition	Transformations of indolent B-cell
	Addition	Iymphomas Transformations of indolent B-cell
	Addition	lymphomas
	Addition	Lymphomas associated with immune
	7 to dicion	deficiency and dysregulation
Classical Hodgkin lymphoma PTLD	No change	Classical Hodgkin lymphoma PTLD
EBV+ mucocutaneous ulcer	Replacement	EBV-positive mucocutaneous ulcer
Plasmacytic hyperplasia PTLD	Replacement	Hyperplasia arising in immune deficiencies (e.g. PTLD)
Infectious mononucleosis PTLD	No change	Infectious mononucleosis PTLD
Monomorphic PTLD (B- and T-/NK-	No change	Monomorphic PTLD (B- and T-/NK-cell
cell types) Polymorphic PTLD	Replacement	types) Polymorphic lymphoproliferative
1 dryffidi pille i TEB	Replacement	disorders arising in immune
		deficiency/dysregulation
Florid follicular hyperplasia PTLD	Removal	,, ,
	Addition	Mature T-cell and NK-cell leukemias
Adult T-cell lymphoma / leukemia (HTLV1 associated)	Replacement	Adult T-cell leukemia/lymphoma
Aggressive NK-cell leukemia	No change	Aggressive NK-cell leukemia
Chronic lymphoproliferative disorder of NK cells	Replacement	NK-large granular lymphocytic leukemia
Sézary syndrome	No change	Sézary syndrome
T-cell large granular lymphocytic	Replacement	T-large granular lymphocytic leukemia
leukemia	·	
	Addition	Primary cutaneous T-cell lymphomas
Mycosis fungoides	No change	Mycosis fungoides



Drives and subsequent CDQ   T call	Danlasana	Deiter and a state of a second CDO and obtained
Primary cutaneous acral CD8+ T-cell lymphoma	Replacement	Primary cutaneous acral CD8-positive lymphoproliferative disorder
Primary cutaneous CD4+	Replacement	Primary cutaneous CD4-positive small or
small/medium T-cell	Replacement	medium T-cell lymphoproliferative
lymphoproliferative disorder		disorder
Primary cutaneous CD8+ aggressive	Replacement	Primary cutaneous CD8-positive
epidermotropic cytotoxic T-cell		aggressive epidermotropic cytotoxic T-
lymphoma		cell lymphoma
Primary cutaneous CD30+ T-cell	Replacement	Primary cutaneous CD30-positive T-cell
lymphoproliferative disorders		lymphoproliferative disorder:
[Primary cutaneous anaplastic large-		lymphomatoid papulosis
cell lymphoma (C-ALCL), lymphoid		
papulosis]	A -l -l'tt'	Discourse CD20 assitive T will
	Addition	Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: primary
		cutaneous anaplastic large cell
		lymphoma
Primary cutaneous γδ T-cell	No change	Primary cutaneous gamma / delta T-cell
lymphoma	ito change	lymphoma
Subcutaneous panniculitis-like T-cell	No change	Subcutaneous panniculitis-like T-cell
lymphoma		lymphoma
	Addition	Primary cutaneous peripheral T-cell
		lymphoma, NOS
	Addition	Intestinal T-cell and NK-cell
		lymphoid proliferations and
Enteronathy type T cell lymphoma	Donlacement	lymphomas
Enteropathy-type T-cell lymphoma	Replacement	Enteropathy-associated T-cell lymphoma
Indolent T-cell lymphoproliferative disorder of the GI tract	Replacement	Indolent T-cell lymphoma of the gastrointestinal tract
disorder of the of tract	Addition	Indolent NK-cell lymphoproliferative
	Addition	disorder of the gastrointestinal tract
Monomorphic epitheliotropic	No change	Monomorphic epitheliotropic intestinal T-
intestinal T-cell lymphoma		cell lymphoma
	Addition	Intestinal T-cell lymphoma, NOS
	Addition	Hepatosplenic T-cell lymphoma
Hepatosplenic T-cell lymphoma	No change	Hepatosplenic T-cell lymphoma
	Addition	Anaplastic large cell lymphoma
Anaplastic large-cell lymphoma	Replacement	ALK-positive anaplastic large cell
(ALCL), ALK positive		lymphoma
Anaplastic large-cell lymphoma	Replacement	ALK-negative anaplastic large cell
(ALCL), ALK negative		lymphoma
Breast implant-associated	Replacement	Breast implant-associated anaplastic
anaplastic large-cell lymphoma	A -l -ltt.	large cell lymphoma
	Addition	Nodal T-follicular helper (TFH) cell
Angioimmunoblastic T coll	Ponlacomont	Nodal TEH coll lymphoma
Angioimmunoblastic T-cell lymphoma	Replacement	Nodal TFH cell lymphoma, angioimmunoblastic-type
туптрпотпа		angioiiiiinunobiastic-type

CIBMTR® is a research collaboration between the Medical College of Wisconsin and NMDP. This document is proprietary and confidential. No part of this may be disclosed in any manner without the prior written consent of CIBMTR.



Follicular T-cell lymphoma	Replacement	Nodal TFH cell lymphoma, follicular-type
Nodal peripheral T-cell lymphoma	Replacement	Nodal TFH cell lymphoma, NOS
with TFH phenotype		
	Addition	Other peripheral T-cell lymphomas
Peripheral T-cell lymphoma (PTCL), NOS	Replacement	Peripheral T-cell lymphoma, NOS
	Addition	EBV-positive NK/T-cell lymphomas
	Addition	EBV-positive nodal T- and NK-cell
		lymphoma
Extranodal NK / T-cell lymphoma, nasal type	Replacement	Extranodal NK / T-cell lymphoma
	Addition	EBV-positive T- and NK-cell
		lymphoid proliferations and
		lymphomas of childhood
Systemic EBV+ T-cell lymphoma of	Replacement	Systemic EBV-positive T-cell lymphoma
childhood		of childhood
Other B-cell lymphoma	No change	Other B-cell lymphoma
Other T-cell / NK-cell lymphoma	No change	Other T-cell / NK-cell lymphoma

## Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion

- "First Name:", "Last Name:", "E-mail address:", "Date:"
  - Removal: The fields to collect data manager contact information have been removed from the form.
  - o <u>Rationale</u>: It is no longer necessary to collect this information, so these fields have been removed to comply with data capture best practices.

CIBMTR® is a research collaboration between the Medical College of Wisconsin and NMDP. This document is proprietary and confidential. No part of this may be disclosed in any manner without the prior written consent of CIBMTR.

Release Date:12/12/2025 Page **6** of **6**